Stock MIRA MIRA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company MIRA Pharmaceuticals, Inc.

Equities

MIRA

US60458C1045

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 11:47:13 2024-07-09 am EDT 		5-day change 1st Jan Change
0.5403 USD -1.37% Intraday chart for MIRA Pharmaceuticals, Inc. -10.35% -48.54%
Jun. 24 MIRA Pharmaceuticals, Inc. Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing CI
Jun. 10 MIRA Pharmaceuticals, Inc. Announces Positive Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year CI

Business Summary

MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.

Managers

Managers TitleAgeSince
Erez Aminov CEO
 Chief Executive Officer 46 23-03-31
Michelle Yanez DFI
 Director of Finance/CFO 52 22-04-30

Members of the board

Members of the board TitleAgeSince
Dave Vorhoff
- -
Michael Jerman BRD
 Director/Board Member 40 Nov. 13
Erez Aminov CEO
 Chief Executive Officer 46 23-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,780,885 10,988,415 ( 74.34 %) 0 74.34 %

Shareholders

NameEquities%Valuation
George Cappy
18.54 %
2,740,270 18.54 % 2 M $
William J Nellis
4.601 %
680,000 4.601 % 433 160 $
Brian McNulty
4.533 %
670,000 4.533 % 426 790 $
Cross Staff Investments, Inc.
2.594 %
383,401 2.594 % 244 226 $
Erez Aminov
2.586 %
382,200 2.586 % 243 461 $
Christopher Chapman
1.353 %
200,000 1.353 % 127 400 $
Adam Kaplin
1.353 %
200,000 1.353 % 127 400 $
Virtu Financial LLC
0.4266 %
63,055 0.4266 % 40 166 $
Brad Kroenig
0.3383 %
50,000 0.3383 % 31 850 $
Hugh McColl
0.2706 %
40,000 0.2706 % 25 480 $

Company contact information

MIRA Pharmaceuticals, Inc.

1200 Brickell Avenue Suite 1950 1183

33131, Miami

+786-432-9792

http://mirapharmaceuticals.com
address MIRA Pharmaceuticals, Inc.(MIRA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MIRA PHARMACEUTICALS, INC. Stock MIRA Pharmaceuticals, Inc.
-48.54% 8.1M
MODERNA, INC. Stock Moderna, Inc.
+16.91% 44.63B
LONZA GROUP AG Stock Lonza Group AG
+42.66% 40.46B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.76% 38.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+33.55% 32.27B
CELLTRION, INC. Stock Celltrion, Inc.
-7.10% 27.3B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.45% 26.53B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+47.11% 14.06B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.89% 12.54B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-8.07% 11.28B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MIRA Stock
  4. Company MIRA Pharmaceuticals, Inc.